letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...2021222324252627282930...100101»
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Transcriptomic analysis reveals the molecular mechanisms underlying osteoclast differentiation in the estrogen-deficient pullets. (Pubmed Central) -  Mar 6, 2023   
    Daily, 0.5 mg/4 mL of letrozole (LZ) was orally administered to the treatment (TRT) group and 4 mL of saline to the control (CON) group of pullets for 6 wk...The variations in candidate genes associated with osteoclast differentiation and cell adhesion may indicate that LZ inhibits E2 biosynthesis, consequently, reduces osteoclast differentiation by suppressing inter-cellular communication and cells attaching to extracellular matrix components. Taken together, the present study demonstrated that inhibiting E2 synthesis during sexual maturity of pullets decreased osteoclast differentiation and considerably enhanced bone quality.
  • ||||||||||  Eligard (leuprolide acetate) / Tolmar, Sanofi
    Trial completion date, Trial primary completion date:  OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov) -  Feb 28, 2023   
    P3,  N=250, Recruiting, 
    Anxiety-like behavior and impaired short-term memory were observed in PCOS rats; however, VCO supplementation reversed these effects by modulating the gene expression of Nrf2 and AchE. Trial completion date: Jun 2024 --> Apr 2025 | Trial primary completion date: Jun 2024 --> Apr 2025
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Enrollment closed, Trial primary completion date:  GOG-3026: Ribociclib and Letrozole Treatment in Ovarian Cancer (clinicaltrials.gov) -  Feb 28, 2023   
    P2,  N=51, Active, not recruiting, 
    Trial completion date: Jan 2023 --> Dec 2025 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2023 --> Dec 2023
  • ||||||||||  letrozole / Generic mfg.
    Biomarker, Review, Journal:  Breast cancer pharmacogenetics: a systematic review. (Pubmed Central) -  Feb 27, 2023   
    Relevant genes in disease treatment pathways were selected to evaluate treatment response from the pharmacogenetic perspective; polymorphism frequencies and ethnic and continental representation across the available literature were also assessed through a systematic review. The identified associations and gaps have been described in this study with the purpose that, in the future, treatments can be personalized and thus be more effective, safer, and accessible to all.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
    Journal:  Pyridine based dual binding site aromatase (CYP19A1) inhibitors. (Pubmed Central) -  Feb 27, 2023   
    letrozole IC 0.70 nM), and an excellent cytotoxicity and selectivity profile. Interestingly, computational studies for the 6-O-butynyloxy (10) and 6-O-pentynyloxy (11) derivatives identified an alternative access channel lined by Phe221, Trp224, Gln225 and Leu477, providing further insight into the potential binding mode and interactions of the non-steroidal aromatase inhibitors.
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
    Trial primary completion date, Metastases:  A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) -  Feb 27, 2023   
    P2,  N=62, Active, not recruiting, 
    Interestingly, computational studies for the 6-O-butynyloxy (10) and 6-O-pentynyloxy (11) derivatives identified an alternative access channel lined by Phe221, Trp224, Gln225 and Leu477, providing further insight into the potential binding mode and interactions of the non-steroidal aromatase inhibitors. Trial primary completion date: Oct 2022 --> Oct 2023
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Journal:  Development and evaluation of novel krill oil-based clomiphene microemulsion as a therapeutic strategy for PCOS treatment. (Pubmed Central) -  Feb 23, 2023   
    Clomiphene citrate, an ovulating agent, is the first-line drug used to treat PCOS...The optimized microemulsion was further evaluated in-vivo using letrozole-induced PCOS rats...The in vivo results were supported by histopathological studies where the formulation-treated group showed a marked decrease in the number of cystic follicles and a remarkable increase in the number of growing follicles at variable stages, similar to the normal control group. Thus, the results confirmed that novel krill oil-based clomiphene microemulsion may become a promising therapeutic choice for the treatment of PCOS.
  • ||||||||||  PF-07248144 / Pfizer
    Enrollment change, Metastases:  C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Feb 23, 2023   
    P1,  N=200, Recruiting, 
    Thus, the results confirmed that novel krill oil-based clomiphene microemulsion may become a promising therapeutic choice for the treatment of PCOS. N=108 --> 200
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (clinicaltrials.gov) -  Feb 22, 2023   
    P1,  N=26, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | N=143 --> 26 | Trial completion date: Jun 2025 --> Jan 2023 | Trial primary completion date: Jun 2023 --> Jan 2023
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole in Induction of Abortion of Anembryonic Pregnancy (clinicaltrials.gov) -  Feb 17, 2023   
    P=N/A,  N=96, Completed, 
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Dec 2024 Trial completion date: Jan 2022 --> Jul 2022 | Trial primary completion date: Jan 2022 --> Jul 2022
  • ||||||||||  letrozole / Generic mfg.
    Journal, Metastases:  When benign leiomyomas metastasize to the lungs - a case report. (Pubmed Central) -  Feb 14, 2023   
    Given the small dimensions and difficult accessibility of the nodules, surgical biopsy was made for histopathological examination and immunohistochemical staining, which were compatible with metastasizing leiomyoma. Treatment with letrozole was initiated and well tolerated.
  • ||||||||||  letrozole / Generic mfg.
    Undergraduate research in organic chemistry course (UROCC): Biological evaluation of heteroaryl tropinones as aromatase inhibitors (Hall F-H (Indiana Convention Center)) -  Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_4840;    
    One example is letrozole, which is an optimum aromatase inhibitor with an IC50 of 9 nM and it is used as first-line therapy for advanced breast cancer...The structural activity relationship for these compounds was analyzed using the obtained percent inhibition, IC50 values, and docking scores. This study provided useful information on the development of aromatase inhibitors as potential agents for breast cancer drugs.
  • ||||||||||  metformin / Generic mfg.
    Preclinical, Journal:  Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. (Pubmed Central) -  Feb 10, 2023   
    Our study confirmed metformin could not only improve body weight and metabolism disorders, but also improve ovarian dysfunction in PCOS mice.In addition, we explored metformin could regulate ferroptosis to improve PCOS via the SIRT3/AMPK/mTOR pathway. Our study complements the mechanisms by which metformin improves PCOS.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells. (Pubmed Central) -  Feb 7, 2023   
    SD rats received a high-fat diet and letrozole for 30 days to establish the PCOS model and then intervened with RES for 30 days...Meanwhile, RES overtly repaired the glycolysis process by reversing the levels of lactic acid and pyruvate, together with up regulating the expression level of LDHA, HK2, and PKM2, after AGK2 treatment. RES could effectively improve insulin resistance and restore the glycolysis pathway by regulating SIRT2, which may contribute to attenuating the ovarian damage of PCOS rats and provide a potential treatment for patients with PCOS.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
    Journal:  A Case of Recurrent Breast Cancer with Multiple Bone Metastasis Effectively Treated by CDK4/6 Inhibitor in Addition to Aromatase Inhibitor (Pubmed Central) -  Feb 4, 2023   
    The treatment of letrozole plus palbociclib(CDK4/6 inhibitor)were continued for 3 months from May 2018, and this therapy made her bone lesions smaller, but palbociclib were stopped due to its severe neutropenia...In February 2019, abemaciclib was administered in addition to letrozole. One year later, her symptoms improved and her bone metastases have showed partial response.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Effects of time-restricted feeding on letrozole-induced mouse model of polycystic ovary syndrome. (Pubmed Central) -  Feb 3, 2023   
    After TRF for 4 weeks, those phenotypes reverted to normal levels in letrozole-treated mice, except the percentage of diestrus cycles indicating the arrest of estrous cycling which did not differ between the TRF and ad libitum groups. Our results demonstrate that TRF has therapeutic effects on the reproductive and metabolic phenotypes of a letrozole-induced mouse model of PCOS.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Journal, Real-world evidence, Real-world:  A real-world study of the effects of endocrine therapy on liver function in breast cancer (Pubmed Central) -  Feb 1, 2023   
    Three aromatase inhibitors (anastrozole, letrozole, and exemestane) and toremifene can significantly increase the level of ALT and AST in patients with breast cancer, and the levels can gradually recover to the baseline after 1 year of drug withdrawal. The effect of non-steroidal aromatase inhibitors (anastrozole, letrozole) on ALT levels is greater than toremifene.
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal, Metastases:  Utility-based Bayesian personalized treatment selection for advanced breast cancer. (Pubmed Central) -  Jan 31, 2023   
    The motivating application is a randomized trial that compared letrozole plus bevacizimab to letrozole alone as first-line therapy for hormone receptor positive advanced breast cancer...Under the fitted model, a new patient's treatment can be selected based on the posterior predictive utility distribution. For the breast cancer trial dataset, the optimal treatment depends on the patient's age, with the combination preferable for patients 70 years or younger and the single agent preferable for patients older than 70.
  • ||||||||||  Trial primary completion date:  EUROPA: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ?70 Years Early Stage Breast Cancer (clinicaltrials.gov) -  Jan 31, 2023   
    P3,  N=926, Recruiting, 
    For the breast cancer trial dataset, the optimal treatment depends on the patient's age, with the combination preferable for patients 70 years or younger and the single agent preferable for patients older than 70. Trial primary completion date: Jan 2026 --> Feb 2025
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) -  Jan 31, 2023   
    P3,  N=80, Recruiting, 
    Trial primary completion date: Jan 2026 --> Feb 2025 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023